Objective: To summarize the nursing experience of infliximab injection in the treatment of Crohn’s disease. Methods: 25 patients with Crohn’s disease admitted to our hospital from November 2017 to February 2024 were treated with infliximab. The therapeutic effect and adverse drug reactions were observed, nursing intervention was given, and follow-up was performed at 2 weeks, 6 weeks after the first treatment and every 2 months after the treatment cycle. According to Crohn’s disease activity index (CDAI) score, 23 cases with ≤4 were classified as remission stage and 2 cases with 6 were classified as mild activity stage. Infliximab-treated Crohn’s patients had a good prognosis and minor adverse reactions. A correct grasp of the basic knowledge of the drug, standardized operation, attention to the psychological state of the patient, close observation of the change of the patient’s condition, and predictability of the treatment of adverse drug reactions are the guarantee of smooth treatment.
References
[1]
Guo, Y.H., Niu, W.W. and Zhang, X.L. (2018) Consensus Opinion on Diagnosis and Treatment of Inflammatory Bowel Disease (Beijing, 2018): A Partial Interpretation of Crohn’s Disease. Clinical Review, 12, 1077-1079 1082.
[2]
Stewart, R.J. and Marsden, P.A. (1995) Biologic Control of the Tumor Necrosis Factor and Interleukin-1 Signaling Cascade. American Journal of Kidney Diseases, 25, 954-966. https://doi.org/10.1016/0272-6386(95)90582-0
[3]
Breese, E.J., Michie, C.A., Nicholls, S.W., et al. (1994) Tumor Necrosis Factor Alpha-Producing Cells in the Intestinal Mucosa of Children with Infammatory Bowel Disease. Gastroenterology, 106, 1455-1466. https://doi.org/10.1016/0016-5085(94)90398-0
[4]
Hu, F.R., Zhang, Q., Zhang, W.J., et al. (2014) Compare Analysis of the Efficacy of Cyclosporin in Treatment of Severe Refractory Ulcerative Colitis. Journal of Gastroenterology and Hepatology, 23, 153-157.
[5]
Inflammatory Bowel Disease Collaboration Group, Chinese Society of Gastroenterology (2012) Consensus Opinion on Diagnosis and Treatment of Inflammatory Bowel Disease (2012). Guangzhou. Chinese Journal of Digestion, 51, 818-831.
Inflammatory Enterology Group, Society of Gastroenterology, Chinese Medical Association (2011) Recommendation of Inflixil in the Treatment of Crohn’s Disease. Chinese Journal of Gastroenterology, 31, 822-824.
[8]
Schnitzler, F., Fidder, H., Ferrante, M., et al. (2009) Long-Term Out-Come of Treatment with Infliximab in 614 Patients with Crohn’s Disease: Results from a Single-Centre Cohort. Gut, 58, 492-500. https://doi.org/10.1136/gut.2008.155812
[9]
Yu, J.F. and Yuan, Y.Z. (2016) Inflicil in The Treatment of Crohn’s Disease Complicated with Fistula Formation: A Clinical Observation. Chinese Journal of Digestion, 29, 10.
[10]
Teng, J. (2018) Application of WeChat in Continuous Care of Inflammatory Bowel Disease. Contemporary Nurses, 2509, 55-56.
